zoledronic acid fresenius kabi 4mg/5ml infusioonilahuse kontsentraat
fresenius kabi polska sp. z o.o. - zoledroonhape - infusioonilahuse kontsentraat - 4mg 5ml 5ml 1tk; 4mg 5ml 5ml 10tk; 4mg 5ml 5ml 4tk
bonefurbit 150 mg õhukese polümeerikattega tablett
orivas uab - ibandroonhape - õhukese polümeerikattega tablett - 150mg 3tk; 150mg 1tk
ossica õhukese polümeerikattega tablett
gedeon richter plc. - ibandroonhape - õhukese polümeerikattega tablett - 50mg 28tk; 50mg 84tk
etanorden õhukese polümeerikattega tablett
gedeon richter plc. - ibandroonhape - õhukese polümeerikattega tablett - 150mg 3tk; 150mg 1tk
licobondrat 150 mg õhukese polümeerikattega tablett
laboratorios liconsa s.a. - ibandroonhape - õhukese polümeerikattega tablett - 150mg 1tk; 150mg 3tk
kefort 150 mg õhukese polümeerikattega tablett
laboratorios liconsa s.a. - ibandroonhape - õhukese polümeerikattega tablett - 150mg 1tk; 150mg 3tk
ibandronic acid ratiopharm süstelahus süstlis
ratiopharm gmbh - ibandroonhape - süstelahus süstlis - 3mg 3ml 3ml 1tk
ibandronic acid ratiopharm infusioonilahuse kontsentraat
ratiopharm gmbh - ibandroonhape - infusioonilahuse kontsentraat - 6mg 6ml 6ml 5tk; 6mg 6ml 6ml 1tk
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastilised ained - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.
evkeeza
ultragenyx germany gmbh - evinacumab - hüperkolesteroleemia - lipiidi modifitseerivad ained - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).